Glaukos Corporation (GKOS) jumps after a strong third-quarter report featuring record sales, rapid corneal-health growth, positive net income, and higher 2026 guidance. The move reflects renewed investor confidence in the company’s ophthalmology platform, though the stock now trades near the top of analyst expectations.
Glaukos Corporation (GKOS) jumps 18.5% after reporting a powerful third quarter that included record $211.0 million in sales, positive net income, and sharply higher corneal-health revenue. The company also raised 2026 guidance, signaling that growth and operating leverage are improving faster than investors expected. For investors, the report strengthens the long-term thesis, but the stock’s surge leaves less room for error at current levels.
Glaukos Corporation (GKOS) Jumps After Q3 Earnings
Glaukos Corporation (GKOS) jumps 18.51% in after-hours trading to $215.01 from its $181.43 regular-session close after a powerful third-quarter report. Record sales, rapid corneal-health growth, positive net income, and higher 2026 guidance drove the repricing, although regular-session trading will confirm whether the move holds.
Key Takeaways
The primary catalyst is Glaukos' October 28, 2026 Q3 earnings report, released after the close.
Q3 net sales reached a record $211.0 million, up 58% year over year, while the company raised 2026 sales guidance.
Corneal health sales surged 154% to $59.0 million, and non-GAAP net income reached $28.5 million.
The stock now trades near the $215 analyst price-target high, making execution more important after the initial jump.
The catalyst is specific: Glaukos reported third-quarter 2026 results after the market closed on October 28. The numbers gave growth-focused investors several reasons to reprice the stock at once.
Net sales reached a record $211.0 million, representing 58% year-over-year growth. That result also exceeded the prior quarter's $185.6 million revenue. U.S. glaucoma sales rose 47% to $118.6 million, while corneal health sales climbed 154% to $59.0 million.
Profitability added another layer to the reaction. Glaukos reported $2.0 million in net income and $28.5 million in non-GAAP net income. Gross margin reached about 85%, while non-GAAP gross margin was about 88%. The company also raised its 2026 net sales guidance.
That combination explains the timing and size of the move better than the recent analyst activity. UBS initiated coverage with a Neutral rating and a $150 price target on October 28, which is not a natural explanation for an 18.51% jump. The earnings report delivered the stronger signal.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How Glaukos Corporation's Q3 Financials Change the Investment Case
Glaukos entered this report with a growth narrative already in motion. In the second quarter, the company posted $185.6 million in revenue, up 50% year over year, and raised full-year guidance to $680 million to $700 million from $620 million to $635 million.
The third-quarter figures extend that pattern. Revenue growth accelerated to 58%, and the company reached positive net income while maintaining gross margins near 85%. For a medical-device company still expanding its commercial footprint, that mix of growth and operating leverage carries more weight than sales growth alone.
The balance sheet also supports the expansion story. Glaukos reported no debt and $289.3 million in cash, equivalents, short-term investments, and restricted cash as of June 30. That financial position gives the company room to fund product development, clinical programs, and commercial expansion without relying on heavy borrowing.
Valuation, however, now demands respect. GKOS has a $10.70 billion market capitalization, and its $215.01 after-hours price sits above the prior 52-week high of $191.62. The consensus analyst target is $192.90, with a $195 median, a $150 low, and a $215 high. In plain English, the after-hours quote has already reached the most optimistic published target.
Glaukos is not dependent on a single ophthalmology product. Its portfolio includes iStent, iStent inject W, and iStent infinite for glaucoma, along with iDose TR for ocular hypertension and glaucoma. The company also sells corneal products such as Photrexa and Epioxa.
That platform gives investors several paths to growth. The Q3 figures show the strongest current momentum in corneal health, where sales grew 154% year over year. Glaucoma remains the larger revenue engine, with U.S. sales of $118.6 million and 47% growth.
The commercial footprint adds scale to that product portfolio. Glaukos has direct operations in 17 countries and more than 300 global commercial personnel. Its pipeline also includes the PRESERFLO MicroShunt in a U.S. active IDE study, alongside earlier-stage retina and cornea programs.
This breadth helps explain why investors value GKOS as an ophthalmology platform rather than a single-product company. Still, a broad pipeline does not remove execution risk. Each product must convert clinical progress into regulatory approval, reimbursement, physician adoption, and recurring sales.
What GKOS Investors Should Do After the Earnings Jump
Existing shareholders have a stronger fundamental case after the report, but the price action changes the risk-reward balance. At $215.01, GKOS trades above its prior 52-week high and near the analyst target ceiling. That makes position sizing more important than chasing the first after-hours print.
New buyers can separate business quality from entry price. The business posted 58% sales growth, an 85% gross margin, positive net income, and higher 2026 guidance. Those facts support the growth thesis. The price, however, now reflects a large portion of that success, so a staged approach offers more discipline than an all-at-once purchase.
The regular session will provide the next practical test. A sustained move near $215 would place the stock at the high end of published analyst expectations. A sharp retreat would show that after-hours liquidity and event-driven enthusiasm temporarily pushed the quote beyond what regular-session buyers accepted.
Glaukos's after-hours jump is fundamentally tied to a strong Q3 report, not vague sector optimism. Record $211.0 million sales, 58% growth, accelerating corneal revenue, positive net income, and raised guidance strengthen the long-term case, while the elevated valuation calls for patience and disciplined entries.
GKOS is up because Glaukos reported a strong Q3 earnings beat with record sales, positive net income, and higher 2026 guidance. The market is also reacting to 154% growth in corneal-health sales and improving profitability.
+Should I buy GKOS stock now?
The earnings report supports the long-term story, but the stock has already moved sharply and is trading near the high end of analyst targets. A staged entry is more prudent than chasing the after-hours spike.
+What did Glaukos report in Q3?
Glaukos reported record net sales of $211.0 million, up 58% year over year, along with $2.0 million in net income and $28.5 million in non-GAAP net income. The company also raised its 2026 sales guidance.
+Is the GKOS rally based on fundamentals or speculation?
The rally is fundamentally driven by the earnings report, not speculation. The move was sparked by strong revenue growth, margin strength, and improved guidance, although the elevated share price now increases valuation risk.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on GKOS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
